Your browser doesn't support javascript.
loading
Low level of Fibrillarin, a ribosome biogenesis factor, is a new independent marker of poor outcome in breast cancer.
Nguyen Van Long, Flora; Lardy-Cleaud, Audrey; Carène, Dimitri; Rossoni, Caroline; Catez, Frédéric; Rollet, Paul; Pion, Nathalie; Monchiet, Déborah; Dolbeau, Agathe; Martin, Marjorie; Simioni, Valentin; Bray, Susan; Le Beherec, Doris; Mosele, Fernanda; Bouakka, Ibrahim; Colombe-Vermorel, Amélie; Odeyer, Laetitia; Diot, Alexandra; Jordan, Lee B; Thompson, Alastair M; Jamen, Françoise; Dubois, Thierry; Chabaud, Sylvie; Michiels, Stefan; Treilleux, Isabelle; Bourdon, Jean-Christophe; Pérol, David; Puisieux, Alain; André, Fabrice; Diaz, Jean-Jacques; Marcel, Virginie.
Afiliação
  • Nguyen Van Long F; Cancer Research Center of Lyon, Université Claude Bernard Lyon 1, INSERM 1052, CNRS 5286, Léon Bérard Cancer Centre, Cheney A, 28 rue Laennec, 69373 cedex 08, Lyon, France.
  • Lardy-Cleaud A; Institut Convergence PLAsCAN, 69373 cedex 08, Lyon, France.
  • Carène D; DevWeCan Labex Laboratory, 69373 cedex 08, Lyon, France.
  • Rossoni C; Biostatistics Unit, Department of Clinical Research, Léon Bérard Cancer Centre, 28 rue Laennec, 69008, Lyon, France.
  • Catez F; Predictive Biomarkers and Novel Therapeutic Strategies Group, Institut Gustave Roussy, University of Paris Sud, INSERM 981, Université Paris Saclay, 114 rue Edouard Vaillant, 94800, Villejuif, France.
  • Rollet P; Department of Biostatistics and Epidemiology, Institut Gustave Roussy, 94800, Villejuif, France.
  • Pion N; Department of Biostatistics and Epidemiology, Institut Gustave Roussy, 94800, Villejuif, France.
  • Monchiet D; Cancer Research Center of Lyon, Université Claude Bernard Lyon 1, INSERM 1052, CNRS 5286, Léon Bérard Cancer Centre, Cheney A, 28 rue Laennec, 69373 cedex 08, Lyon, France.
  • Dolbeau A; Institut Convergence PLAsCAN, 69373 cedex 08, Lyon, France.
  • Martin M; DevWeCan Labex Laboratory, 69373 cedex 08, Lyon, France.
  • Simioni V; Cancer Research Center of Lyon, Université Claude Bernard Lyon 1, INSERM 1052, CNRS 5286, Léon Bérard Cancer Centre, Cheney A, 28 rue Laennec, 69373 cedex 08, Lyon, France.
  • Bray S; Institut Convergence PLAsCAN, 69373 cedex 08, Lyon, France.
  • Le Beherec D; DevWeCan Labex Laboratory, 69373 cedex 08, Lyon, France.
  • Mosele F; Cancer Research Center of Lyon, Université Claude Bernard Lyon 1, INSERM 1052, CNRS 5286, Léon Bérard Cancer Centre, Cheney A, 28 rue Laennec, 69373 cedex 08, Lyon, France.
  • Bouakka I; Institut Convergence PLAsCAN, 69373 cedex 08, Lyon, France.
  • Colombe-Vermorel A; DevWeCan Labex Laboratory, 69373 cedex 08, Lyon, France.
  • Odeyer L; Cancer Research Center of Lyon, Université Claude Bernard Lyon 1, INSERM 1052, CNRS 5286, Léon Bérard Cancer Centre, Cheney A, 28 rue Laennec, 69373 cedex 08, Lyon, France.
  • Diot A; Institut Convergence PLAsCAN, 69373 cedex 08, Lyon, France.
  • Jordan LB; DevWeCan Labex Laboratory, 69373 cedex 08, Lyon, France.
  • Thompson AM; Cancer Research Center of Lyon, Université Claude Bernard Lyon 1, INSERM 1052, CNRS 5286, Léon Bérard Cancer Centre, Cheney A, 28 rue Laennec, 69373 cedex 08, Lyon, France.
  • Jamen F; Institut Convergence PLAsCAN, 69373 cedex 08, Lyon, France.
  • Dubois T; DevWeCan Labex Laboratory, 69373 cedex 08, Lyon, France.
  • Chabaud S; Cancer Research Center of Lyon, Université Claude Bernard Lyon 1, INSERM 1052, CNRS 5286, Léon Bérard Cancer Centre, Cheney A, 28 rue Laennec, 69373 cedex 08, Lyon, France.
  • Michiels S; Institut Convergence PLAsCAN, 69373 cedex 08, Lyon, France.
  • Treilleux I; DevWeCan Labex Laboratory, 69373 cedex 08, Lyon, France.
  • Bourdon JC; Cancer Research Center of Lyon, Université Claude Bernard Lyon 1, INSERM 1052, CNRS 5286, Léon Bérard Cancer Centre, Cheney A, 28 rue Laennec, 69373 cedex 08, Lyon, France.
  • Pérol D; Institut Convergence PLAsCAN, 69373 cedex 08, Lyon, France.
  • Puisieux A; DevWeCan Labex Laboratory, 69373 cedex 08, Lyon, France.
  • André F; Tayside Tissue Bank, Ninewells Hospital and Medical School, NHS Tayside, Dundee, DD1 9SY, Scotland, UK.
  • Diaz JJ; Department Translational Research, Institut Gustave Roussy, 94800, Villejuif, France.
  • Marcel V; Predictive Biomarkers and Novel Therapeutic Strategies Group, Institut Gustave Roussy, University of Paris Sud, INSERM 981, Université Paris Saclay, 114 rue Edouard Vaillant, 94800, Villejuif, France.
BMC Cancer ; 22(1): 526, 2022 May 11.
Article em En | MEDLINE | ID: mdl-35545761
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Guideline / Prognostic_studies Limite: Female / Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Guideline / Prognostic_studies Limite: Female / Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article